Physician profile
Joel D Starnes
NPI 1568670396
$6,259.61
in general payments reported to CMS, 2019-2025
27 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $642 · 2021: $803 · 2022: $949 · 2023: $948 · 2024: $1,584 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081 · Education: $96.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,080.73 |
| Education | $96.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,322.83 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $1,273.78 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $753.76 | 2022-2025 | |
| Amgen INC. | $469.38 | 2019-2025 | Tavneos, Krystexxa |
| Akebia Therapeutics INC | $258.12 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $247.89 | 2023-2025 | |
| Nuwellis, INC. | $231.86 | 2020-2021 | |
| Horizon Therapeutics Plc | $188.84 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.20 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $168.02 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $143.26 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $142.79 | 2020-2021 | |
| Fresenius USA Marketing, INC. | $123.52 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $120.44 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $104.79 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $74.69 | 2019 | |
| Novo Nordisk INC | $70.99 | 2024-2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $63.84 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $63.51 | 2021-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $62.06 | 2024-2025 | |
| Ardelyx, INC. | $60.46 | 2024-2025 | Ibsrela |
| Veloxis Pharmaceuticals, INC. | $29.24 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.84 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.07 | 2021 | |
| Genzyme Corporation | $18.55 | 2021 | |
| Amarin Pharma, INC. | $17.35 | 2019 | |
| Shire North American Group INC | $16.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Starnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.